All stock lists
Evolus, Inc. (EOLS)
NASDAQ: EOLS · Real-Time Price · USD
Healthcare · Drug Manufacturers - Specialty & Generic
7.14+0.13 (+1.85%)
Insider Score
––Not scored
EOLS Insider Score
Insiders filed in the last 90 days, but none of those trades qualified for scoring — round-trip buys and filings whose price is far off the market are excluded.
EOLS Stock Insider Trading Activity
EOLS stock’s insider trading shows 1 sale on the open market for an estimated $950.02K by company insiders over the last 6 months.
Not enough price history.
Insider Trading Activity (Form 4 Filings)
An insider trade occurs when an individual that has non-public information about a company buys or sells shares of that company’s stock. Examples of insiders include a company’s executive officers (CEO, CFO, COO), its board of directors, and its major shareholders. Insiders are required to submit their trading activity to the SEC through Form 4 filings.
Scored window · last 90 days0 qualifying buys0 insiders$0 bought— these are the numbers in the rankings table; the full history below shows every filing (buys, sells and older activity).
| Insider | Action | Shares | Avg Cost | Total | Δ Holdings | Held After | Date | Grade | Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| MOATAZEDI DAVID Director | Sell | 105,108 | $9.04 | $950.02K | 17.4% | 499,592 | Sep 2, 2026 | — | Form 4 |
| Avelar Rui Other | Sell | 3,119 | $4.75 | $14.82K | 0.7% | 427,423 | Mar 20, 2026 | — | Form 4 |
| MOATAZEDI DAVID Director | Sell | 13,669 | $4.75 | $64.93K | 2.2% | 604,700 | Mar 20, 2026 | — | Form 4 |
| Avelar Rui Other | Sell | 29,996 | $4.89 | $146.68K | 6.5% | 430,542 | Mar 17, 2026 | — | Form 4 |
| MOATAZEDI DAVID Director | Sell | 116,720 | $4.89 | $570.76K | 15.9% | 618,369 | Mar 17, 2026 | — | Form 4 |
| MOATAZEDI DAVID Director | Option exercise | 67,489 | — | — | 10.1% | 735,089 | Mar 16, 2026 | — | Form 4 |
| Avelar Rui Other | Option exercise | 8,804 | — | — | 1.9% | 460,538 | Mar 16, 2026 | — | Form 4 |
| GILL DAVID N Director | Award | 45,559 | — | — | 110% | 86,887 | Feb 17, 2026 | — | Form 4 |
| MOATAZEDI DAVID Director | Award | 313,212 | — | — | 88.4% | 667,600 | Feb 17, 2026 | — | Form 4 |
| Mitchell Tatjana CFO | Award | 121,489 | — | — | 116% | 226,092 | Feb 17, 2026 | — | Form 4 |
| Stewart Brady Director | Award | 45,559 | — | — | 51.4% | 134,188 | Feb 17, 2026 | — | Form 4 |
| White Albert G III Director | Award | 45,559 | — | — | 90.4% | 95,937 | Feb 17, 2026 | — | Form 4 |
| Malik Vikram Director | Award | 45,559 | — | — | 16.5% | 321,109 | Feb 17, 2026 | — | Form 4 |
| Parschauer Karah Herdman Director | Award | 45,559 | — | — | 142% | 77,742 | Feb 17, 2026 | — | Form 4 |
| Avelar Rui Other | Award | 94,913 | — | — | 26.6% | 451,734 | Feb 17, 2026 | — | Form 4 |
| Avelar Rui Other | Sell | 2,261 | $7.15 | $16.17K | 0.6% | 356,821 | Dec 22, 2025 | — | Form 4 |
| MOATAZEDI DAVID Director | Sell | 10,539 | $7.15 | $75.35K | 2.9% | 354,388 | Dec 22, 2025 | — | Form 4 |
| Mitchell Tatjana CFO | Award | 104,603 | — | — | New | 104,603 | Sep 8, 2025 | — | Form 4 |
What these mean— the action is the SEC’s own Form 4 transaction code. Only a buy or a sell is an open-market trade; the rest are transfers, awards and exercises, which is why they carry no price.
- Sell (S) — Open-market or private sale
- Award (A) — Grant or award from the company, not a purchase
- Option exercise (M) — Exercise or conversion of an exempt derivative
Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.